Sacituzumab govitecan significantly improves progression-free survival and overall survival in metastatic breast cancer
Sacituzumab Govitecan Shows Improved Survival for Metastatic Breast Cancer
This meta-analysis of 1,900 patients with metastatic breast cancer found that sacituzumab govitecan significantly prolonged progression-free…
Sacituzumab govitecan may improve survival and progression-free time for patients with metastatic breast cancer compared to standard chemoth…
Neoadjuvant sacituzumab govitecan plus pembrolizumab shows 39% clinical complete response in MIBC
Drug combination shows promise for bladder cancer patients who cannot take standard chemotherapy
A single-arm phase 2 study of 49 patients with muscle-invasive bladder cancer ineligible for cisplatin found a clinical complete response ra…
A new drug combination helped 39% of bladder cancer patients who couldn't take standard chemotherapy achieve a complete response before surg…